Considering the contribution of PI3K/Akt and JNK pathways to GBM progression and chemoresistance to a wide range of therapeutics, these results may help to further define potential therapeutic targets for effective GBM therapy [3,5]. This evidence concerns the gene AKT1 and glioblastoma.